From the Division of Cardiothoracic Transplantation and Circulatory Support, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Department of Cardiopulmonary Transplantation and the Center for Cardiac Support, Texas Heart Institute, Houston, Texas.
ASAIO J. 2020 May;66(5):539-546. doi: 10.1097/MAT.0000000000001044.
In this study, we sought to determine the accuracy of several critical care risk scores for predicting survival of Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Profile 1 patients after continuous-flow left ventricular assist device (CF-LVAD) placement. We retrospectively analyzed the records of 605 patients who underwent CF-LVAD implantation between 2003 and 2016. We calculated the preoperative HeartMate II Risk Score (HMRS) and preoperative Right Ventricular Failure Risk Score (RVFRS) and the following risk scores for postoperative days 1-5: HMRS, RVFRS, Model for End-stage Liver Disease (MELD), MELD-eXcluding International Normalized Ratio, Post Cardiac Surgery (POCAS) risk score, Sequential Organ Failure Assessment (SOFA) risk score, and Acute Physiology and Chronic Health Evaluation III. The preoperative scores and the postoperative day 1, 5-day mean, and 5-day maximum scores were entered into a receiver operating characteristic curve analysis to examine accuracy for predicting 30-day, 90-day, and 1-year survival. The mean POCAS score was the best predictor of 30-day and 90-day survival (area under the curve [AUC] = 0.869 and 0.816). The postoperative mean RVFRS was the best predictor of 1-year survival (AUC = 0.7908). The postoperative maximum and mean RVFRS and HMRS were more accurate than the preoperative scores. Both of these risk score measurements of acuity in the postoperative intensive care unit setting help predict early mortality after LVAD implantation.
在这项研究中,我们旨在确定几种关键的重症监护风险评分在预测连续流动左心室辅助装置(CF-LVAD)植入后 INTERMACS Profile 1 患者生存的准确性。我们回顾性分析了 2003 年至 2016 年间接受 CF-LVAD 植入的 605 例患者的记录。我们计算了术前 HeartMate II 风险评分(HMRS)和术前右心室衰竭风险评分(RVFRS),以及术后第 1-5 天的以下风险评分:HMRS、RVFRS、终末期肝病模型(MELD)、不包括国际标准化比值的 MELD、心脏手术后(POCAS)风险评分、序贯器官衰竭评估(SOFA)风险评分和急性生理学和慢性健康评估 III。将术前评分和术后第 1 天、5 天平均值和 5 天最大值输入到接收者操作特征曲线分析中,以检查预测 30 天、90 天和 1 年生存率的准确性。平均 POCAS 评分是预测 30 天和 90 天生存率的最佳预测因子(曲线下面积 [AUC] = 0.869 和 0.816)。术后平均 RVFRS 是预测 1 年生存率的最佳预测因子(AUC = 0.7908)。术后最大和平均 RVFRS 和 HMRS 比术前评分更准确。这两种术后重症监护病房急性评分有助于预测 LVAD 植入后的早期死亡率。